Regulatory Affairs and Pharmacovigilance in Belarus: A Practical Guide for Pharma Companies

Regulatory affairs and pharmacovigilance in Belarus require a coordinated understanding of national legislation and EAEU requirements.

Regulatory Affairs and Pharmacovigilance in Belarus: A Practical Guide for Pharma Companies

Introduction

Belarus is an important pharmaceutical market within the Eurasian Economic Union (EAEU). Companies seeking to register, manufacture or distribute medicinal products in the country must navigate national legislation alongside the EAEU's harmonized regulatory framework.

The Ministry of Health of the Republic of Belarus oversees national medicines policy, while the Center for Expertise and Testing in Health Care plays an important role in the expert assessment of medicinal products. EAEU requirements also influence registration dossiers, good manufacturing practice (GMP) and pharmacovigilance.

For pharmaceutical companies, understanding how these systems interact is essential. A well-planned regulatory approach can support efficient submissions, reliable safety monitoring and consistent product quality throughout the lifecycle.

  1. Understanding Belarus's Pharmaceutical Regulatory Framework

Belarus regulates medicinal products through national legislation, including the Law on Medicines and relevant government resolutions. As an EAEU member, it also applies common rules covering registration, examination, manufacturing quality and pharmacovigilance.

Two frameworks are particularly important:

  • National requirements: Belarusian legislation governments domestic regulatory administration, competent-authority interactions and applicable national procedures.
  • EAEU requirements: Common Union rules establish harmonized standards for medicinal product registration, GMP and pharmacovigilance.

Companies should establish which registration route and regulatory provisions apply to their product. Transitional arrangements and amendments to national legislation can affect existing authorizations and submission planning. Therefore, businesses should verify the current status of each product rather than assuming that one procedure applies universally.

A country-specific assessment of Regulatory Affairs Services in Belarus can help organizations identify relevant regulatory activities before preparing an application.

  1. Medicinal Product Registration and Dossier Requirements

The EAEU registration framework is based on common procedures for the registration and examination of medicinal products for human use. The dossier follows the Common Technical Document (CTD) structure, with regional administrative requirements included in Module 1.

The five CTD modules cover:

  • Module 1: Administrative and regional information.
  • Module 2: Quality, non-clinical and clinical summaries.
  • Module 3: Pharmaceutical quality and manufacturing data.
  • Module 4: Non-clinical study reports.
  • Module 5: Clinical study reports.

Applicants should ensure that the dossier is complete, internally consistent and aligned with the applicable EAEU requirements. Particular attention is needed for translations, product information, manufacturing-site documentation and evidence supporting quality and safety.

Companies should also consider the regulatory status of existing national authorizations. Belarusian Resolution No. 254 of 2015, as amended, addresses state registration and confirmation of registration of medicines. Its current provisions should be reviewed alongside applicable EAEU rules when planning new applications or managing established products.

  1. Pharmacovigilance Responsibilities

Pharmacovigilance is a continuing responsibility for marketing authorization holders (MAHs). The EAEU Good Pharmacovigilance Practice (GVP) Rules, approved by Council Decision No. 87 of 3 November 2016 and subsequently amended, provide the common framework for medicine safety monitoring.

MAHs must maintain systems to identify, assess and report suspected adverse reactions. Core responsibilities include:

  • Maintaining an effective pharmacovigilance system.
  • Appointing a qualified person responsible for pharmacovigilance in accordance with applicable EAEU requirements.
  • Maintaining a pharmacovigilance system master file (PSMF).
  • Collecting, assessing and submitting applicable individual case safety reports (ICSRs).
  • Preparing periodic safety update reports (PSURs), where required.
  • Maintaining risk management plans (RMPs), where applicable.
  • Identifying safety signals and implementing appropriate risk-minimization measures.

Companies should define clear procedures for receiving safety information from healthcare professionals, patients, distributors and business partners. Agreements with local representatives and service providers should specify reporting responsibilities, timelines and escalation procedures.

EAEU rules also provide for pharmacovigilance system inspections. The Eurasian Economic Commission introduced common inspection provisions in 2024, supporting more consistent oversight across member states.

Organizations reviewing local safety processes can explore Pharmacovigilance Services in Belarus when assessing the systems and responsibilities needed to support ongoing compliance.

  1. GMP Compliance and Manufacturing Oversight

GMP compliance helps ensure that medicines are consistently manufactured and controlled according to appropriate quality standards. Under the EAEU framework, manufacturers must meet the Union's GMP requirements, supported by pharmaceutical inspection and certification processes.

Regulatory assessments may examine:

  • Manufacturing authorizations and site information.
  • Quality management systems and standard operating procedures.
  • Personnel training and responsibilities.
  • Equipment qualification and process validation.
  • Deviation management and corrective and preventive actions (CAPA).
  • Batch records, testing and product release controls.

Companies should assess the compliance status of every relevant manufacturing site, including outsourced facilities. A current certificate alone may not provide a complete picture; inspection findings, scope, manufacturing activities and subsequent changes also matter.

A structured approach to GMP Compliance Services can support organizations reviewing manufacturing controls and preparing for regulatory inspections.

  1. API Documentation and Lifecycle Management

Active pharmaceutical ingredient (API) documentation is a critical part of medicinal product quality assessment. Applicants must provide suitable information about API manufacture, specifications, controls, impurities and stability.

The EAEU dossier framework allows relevant API master file information to support quality assessment, subject to applicable requirements. Companies should coordinate closely with API manufacturers to ensure that confidential information is made available to the competent authority through the appropriate procedure.

Important considerations include:

  • Maintaining consistency between the API master file and finished product dossier.
  • Reviewing supplier changes and manufacturing-process updates.
  • Assessing the impact of specification or analytical-method changes.
  • Keeping supporting quality and stability information current.
  • Documenting communication between API suppliers and MAHs.

Appropriate API DMF Services can help organizations coordinate technical documentation and maintain consistency across regulatory submissions.

Why Choose DDReg as your Consulting Partner

For organizations exploring broader regulatory considerations, Life Science Consulting Services provide a starting point for further industry information. Regulatory Intelligence Tools can support awareness of changing requirements, while Regulatory Affairs Lifecycle Management offers further context on coordinating regulatory activities over time.

Conclusion

Regulatory affairs and pharmacovigilance in Belarus require a coordinated understanding of national legislation and EAEU requirements. Companies must manage registration pathways, maintain reliable dossier information, monitor medicine safety and ensure manufacturing sites meet applicable GMP standards.

Regular regulatory monitoring, clear accountability and effective documentation control help organizations respond to changes and maintain compliance throughout a medicine's lifecycle.


DDReg Pharma

19 ब्लॉग पदों

टिप्पणियाँ